Patel Nupur U, Felix Kayla, Reimer Danielle, Feldman Steven R
Center for Dermatology Research, Department of Dermatology.
Department of Pathology.
Clin Cosmet Investig Dermatol. 2017 Sep 29;10:385-391. doi: 10.2147/CCID.S131727. eCollection 2017.
While topical medications remain the cornerstone of the psoriasis treatment paradigm, they also come with the risk of multiple side effects. An alternative topical treatment option, calcipotriene or calcipotriol, is a vitamin D derivative that is thought to work by inhibiting keratinocyte proliferation and enhancing keratinocyte differentiation. Multiple studies have demonstrated its efficacy and safety in improving psoriasis when used in combination with topical corticosteroids. Given the effectiveness and side effect profile seen with this combination of topical steroid and calcipotriene, the US Food and Drug Administration approved a calcipotriene/betamethasone dipropionate product for use in psoriasis patients over the age of 12 in 2006. Our paper seeks to review clinical trial evidence of this combination medication and its use in the treatment of psoriasis vulgaris. While assessment of available evidence indicates that the topical medication is both safe and effective for the treatment of psoriasis vulgaris, addressing limitations of what is known, such as tolerability, adherence, and patient preference, of this combination drug in future high-impact studies is needed.
虽然局部用药仍然是银屑病治疗模式的基石，但它们也存在多种副作用的风险。一种替代的局部治疗选择，卡泊三烯或骨化三醇，是一种维生素D衍生物，被认为通过抑制角质形成细胞增殖和增强角质形成细胞分化来发挥作用。多项研究表明，当与外用糖皮质激素联合使用时，它在改善银屑病方面具有有效性和安全性。鉴于外用类固醇和卡泊三烯联合使用的有效性和副作用情况，美国食品药品监督管理局于2006年批准了一种卡泊三烯/倍他米松二丙酸酯产品用于12岁以上的银屑病患者。我们的论文旨在回顾这种联合用药的临床试验证据及其在寻常型银屑病治疗中的应用。虽然对现有证据的评估表明局部用药对寻常型银屑病的治疗既安全又有效，但在未来的高影响力研究中仍需要解决这种联合药物已知的局限性，如耐受性、依从性和患者偏好等问题。
